Literature DB >> 24944925

A cross-sectional study of polycystic ovarian syndrome among adolescent and young girls in Mumbai, India.

Beena Joshi1, Srabani Mukherjee2, Anushree Patil1, Ameya Purandare3, Sanjay Chauhan1, Rama Vaidya4.   

Abstract

INTRODUCTION: Polycystic ovary disease is a common endocrine condition which is rapidly gaining epidemic proportions. No community based prevalence data is available for this syndrome in India.
MATERIALS AND METHODS: A cross-sectional community-based study was undertaken in a sampled census block of Mumbai to assess the prevalence of polycystic ovarian syndrome (PCOS) among 778 adolescents and young girls aged 15-24 years. Among them, 600 completed all clinical, ultrasonography (USG), and biochemical investigations.
RESULTS: The prevalence of PCOS among them was 22.5% by Rotterdam and 10.7% by Androgen Excess Society criteria. Nonobese comprised 71.8% of PCOS diagnosed by Rotterdam criteria. Mild PCOS (oligomenorrhea and polycystic ovaries on USG) was the most common phenotype (52.6%). History of oligomenorrhea had a positive predictive value of 93.3% and negative predictive value of 86.7% to detect a possible case of PCOS. Hyperinsulinemia (serum insulin >15 μlU/mL) was present among 19.2% of diagnosed PCOS cases. Obese girls with PCOS were more hirsute, hypertensive, and had significantly higher mean insulin and 2 h post 75 g glucose levels compared with nonobese PCOS.
CONCLUSION: To our knowledge, this is the first urban community-based study diagnosing PCOS and phenotypes among adolescent and young girls in India. This study demonstrates that PCOS is an emerging disorder during adolescence and screening could provide opportunity to target the group for promoting healthy lifestyles and early interventions to prevent future morbidities.

Entities:  

Keywords:  Adolescents; India; phenotypes; polycystic ovarian syndrome; prevalencte

Year:  2014        PMID: 24944925      PMCID: PMC4056129          DOI: 10.4103/2230-8210.131162

Source DB:  PubMed          Journal:  Indian J Endocrinol Metab        ISSN: 2230-9500


INTRODUCTION

Polycystic ovarian syndrome (PCOS) is one of the most common reproductive endocrinological disorders with a broad spectrum of clinical manifestations affecting about 6-8% of women of reproductive years.[1] The diverse manifestations of PCOS start at an early age when a girl is maturing into a young woman. During this pubertal transition, several features may be in evolution and thus many findings may be transitory which stabilize later during adolescence. However, it is important to make an early diagnosis in order to prevent early and late sequel of the syndrome. PCOS a diagnosis of exclusion has been a topic of debate and many consensus definitions have evolved over time. The National Institute for Health (NIH) Criteria 1990 was revised in 2003 and Rotterdam criteria[2] has been adopted world over. However, recently in 2006, Androgen Excess Society (AES) has come up with a consensus statement, defining PCOS as a hyperandrogenic state and emphasises the presence of either clinical and/or biochemical features of hyperandrogenism along with other features of PCOS for diagnosis.[3] Globally, prevalence estimates of PCOS are highly variable, ranging from 2.2% to as high as 26%.[45678] Community-based studies using Rotterdam criteria among reproductive age group women have demonstrated varied prevalence figures in few Asian countries ranging from 2% to 7.5% in China[910] to 6.3% in Srilanka.[11] Studies among several Caucasian populations using NIH criteria reported PCOS in the range of 5-8%.[456789101112] An Australian retrospective birth cohort study of 728 women reported a prevalence of 11.9 ± 2.4% as per Rotterdam criteria, which increased to 17.8 ± 2.8% when imputed data were included. Under the AES recommendations, PCOS prevalence was 10.2 ± 2.2%, and 12.0 ± 2.4% with the imputed data.[13] Although there are limited studies of PCOS in India, the observational studies by endocrinologists, gynecologists, and dermatologists relate to diverse aspects of PCOS. Prevalence of obesity and diabetes mellitus in most industrialized countries including India is also on the rise owing to urbanization and change in lifestyle. Most of the young population do not visit health facilities until they have late sequel of the problem. Most prevalence studies in India are in hospital set-ups and recently a few studies among adolescents in schools report prevalence of PCOS as 9.13% to 36%.[1415] It is appropriately pointed by Gainie and Kalra[16] that the health budget of India is unlikely to meet the costs posed to tackling the associated multiple consequences of PCOS. It is time that this warning is heeded and at national level the disease is recognized as an important noncommunicable disease.[17] Studies have demonstrated that the cost of diagnostic evaluation accounts only for a relatively minor part of the total costs of managing PCOS (approximately 2%). Hence, more widespread and liberal screening for the disorder appears to be a cost-effective strategy, benefiting earlier diagnosis and intervention and possibly the amelioration and prevention of serious sequel.[1] The varying prevalence of PCOS in general is mainly due to using different diagnostic criteria, the heterogeneous presentation of symptoms, logistic difficulty to carry out blood or ultrasound tests, and the varied age groups and ethnic populations that have been studied. This has resulted in prevalence studies being based on convenience samples such as university employees.[45678] or blood donors.[7] without any representativeness of these subgroups. With this background, a community-based study was undertaken in Mumbai, India to screen adolescents and young unmarried girls aged 15-24 years for PCOS.

MATERIALS AND METHODS

A community-based cross-sectional study, using a systematic multistage random sampling method was conducted in a sampled census block of Mumbai from July 2010 to December 2011. A sample size of 900 was calculated assuming a prevalence of 10% and precision of 2% at 95% confidence level. Considering a nonresponse rate of 10% the total sample to be enrolled was estimated to be about 1000 cases. Girls aged 15-24 years, who had attained menarche more than 2 years before the study, who were unmarried and were willing to participate in the study were enrolled. An estimate of 10,600 eligible girls in the sampled area was derived considering that the block with a population of approximately 80,000 would have 19% female population in the age group of 15-24 years[18] and 30% of them would have been married and hence would be excluded. Using census data checklist of households in the sampled area, adolescent and young girls from every 10th household were approached. If a household had more than one girl who fit into the inclusion criteria, all were invited to participate in the study.

Operational definitions

Adolescents

Age group 10-19 years (for our study 15-19 years).

Young girls

Age group 20-24 years.

Amenorrhoea

In a girl who has been menstruating, the absence of periods for a length of time equivalent to a total of at least 3 of the previous cycle intervals or 6 months of amenorrhea.

Oligomenorrhea

Indirect marker for anovulation in absence of any hormonal evidence, but considering infrequent menstrual cycles at intervals of more than 35 days.

Body mass index[1920]

Normal: BMI = 18-22.9 kg/m2, Underweight: BMI < 17.9 kg/m2, Overweight: BMI > 23 kg/m2, Obese: BMI > 25 kg/m2 for girls above 18 years.[18] Age matched cut offs for body mass index (BMI) for girls below 18 years.[19]

Clinical hyperandrogenism

Hirsutism was assessed by Ferriman-Gallwey.[21] score of ≥8 over 9 body parts.

Polycystic ovaries

12 or more follicles measuring 2-9 mm in diameter with or without ovarian volume >10 mL.[22]

Biochemical hyperandrogenism

Free Androgen Index level of two standard deviations above the mean level among normal controls (Formula: Total testosterone/SHbg × 100).

Probable PCOS

Signs and symptoms mimic PCOS but etiology not confirmed (without differential diagnosis of other etiologies).

Metabolic syndrome (International harmonization definition)[23]

Any three of the following criteria (i) waist circumference ≥80 cm, (ii) serum triglyceride ≥1.7 mmol/L, (iii) serum high-density lipoprotein cholesterol <1.3 mmol/L, (iv) blood pressure ≥130/85 mm Hg, and (v) fasting blood sugar of >100 g/dL.

Phenotypes

Based on signs and symptoms such as oligomenorrhea, Polycystic ovaries (PCO appearance on ultrasonography (USG), clinical and biochemical hyperandrogenism, the phenotypes are classified from A to J (3) [Table 3] and further grouped together.[24] as mild PCOS (phenotype J), Frank PCOS (phenotype A, C, and E), classic PCOS (phenotypes B, D, and F), and ovulatory PCOS (phenotypes G, H, and I).
Table 3

Polycystic ovarian synrdome phenotypes

Community level enrolment

After obtaining ethical approvals from Institute Ethics Committee, 1000 girls were approached at household level and were explained about the study. About 778 consented to participate in the study. Girls were enrolled after taking an informed written consent from them and also their parents/guardians if they were minors (<18 years). At enrolment, girls were educated on PCOS using a pretested information brochure in local language. An equipped field clinic manned by a medical doctor and a laboratory assistant was established in the study area with the cooperation extended by the Municipal Corporation of Greater Mumbai. A list of all households in the area was obtained from census data. Eligible girls in the selected household were invited to participate in the study and trained investigators administered a structured questionnaire.

Clinical examination and investigations

All enrolled girls irrespective of their menstrual patterns were asked to attend the field clinic for clinical examination and investigations. Physicians involved in the study had adequate clinical experience and were guided by consultant experts for quality control. Apart from personal information, details of menstrual cycles (current and over last 2 years), any previous illness, treatment sought, were noted. Height in meters, weight in kgs, and blood pressure (mm Hg) were measured using standard methods. Signs of hyperandrogenism, galactorrhea, and thyroid disorders were noted. All the girls were then subjected to abdominal sonography performed twice a week at a center operated by an Nongovernment organization in a nearby locality, by a single trained gynaecologist and sonologist using HD6 Ultrasound Colour Doppler system. A fasting blood sample was collected between 3rd and 7th days of menstrual cycle, including for those who had cycle length of 6-8 weeks and stored at -80°C for biochemical and hormonal parameters. The laboratory was blinded to the diagnosis. Total testosterone, insulin and SHBG levels were estimated by radioimmunoassay method using commercial kits (Diasorin, Stillwater USA and Izotop, Budapest, Hungary respectively). Enzyme-linked immunosorbent assay was used to measure follicle-stimulating hormone, lieutinizing hormone, serum prolactin (PRL) 17-hydroxy progesterone (17-OHP), thyroxine (T4), and thyroid-stimulating hormone using commercially available kits (Syntron Bioresearch, Inc., Carslbad USA). Glucose oxidase-peroxidase method was used to estimate blood glucose. Lipid profile was estimated by using enzymatic colorimetric technique. Manufacturer's instructions were followed for preparation, set-up, dilutions, adjustments, assay, and quality control procedures. Among the screened girls, those who had normal cycles were clinically normal including BMI, no clinical hyperandrogenism and had no PCO morphology on USG were considered as non PCOS group for comparison.

Statistical analysis

Data were analyzed in the Statistical Package for the Social Sciences software (version 19.0, IBM SPSS Statistics). Frequencies and percentages were used for categorical data. Mean, median, and standard deviations were calculated for continuous variables. Pearson's Chi-square test was used to assess differences in the groups for categorical data. All hypothesis tests were two sided and P < 0.05 were considered statistically significant. Distributions were compared using “unpaired Student's t test.”

RESULTS

A total of 1000 girls in the area fulfilling the inclusion criteria were invited to participate in the study to achieve a sample size of 900. Among them, only 778 girls volunteered, got enrolled and underwent clinical examination. However, only 687 of them completed ultrasound examination (88.3%) and 600 of them completed all the biochemical and hormonal tests (77%) [Figure 1].
Figure 1

Flow of study participants

Flow of study participants The nonparticipation rate for enrolment was 13.5% unlike the assumed 10%. Further drop out at stage two for sonography examination was 11.7% and 12.7% during the last stage, that is, for blood investigations. Participants were considered as dropouts when they failed to come for required visits even after five rounds of home-based health educative sessions with validated written information brochures. Reasons for dropout, as informed by participants, included refusal by parents, marriage and/or shift of residence, absence of clinical complaints (in about 80% of drop outs), unwillingness for investigations, and inconvenience to come fasting between 3rd and 7th days of the cycle for blood investigations due to work/educational schedule. The mean age of the participants was 18.15 (±2.4) years. Majority of the participants (73.2%) were adolescents (15-19 years) from lower socioeconomic strata. The mean age at menarche was 13.22 (±1.3) years. We divided the enrolled girls into three groups as shown in Table 1. Group A comprised of girls who completed all desired investigations (n = 600), Group B were girls who completed only clinical and ultrasonography examinations (n = 87), and Group C who underwent only clinical examination (n = 91). As seen in the Table 1, all three groups had similar mean ages. All groups had mean BMI within normal range. History of irregular cycles was more among girls in Group A and feature of huirsuitism was more in Group C. Groups A and C had almost same number of girls with PCO picture on USG.
Table 1

Differences in the three groups of enrolled girls

Differences in the three groups of enrolled girls

Prevalence of PCOS and their phenotypes

Among those who underwent clinical and sonographic assessment, probable PCOS was diagnosed among 22.85% using Rotterdam criteria (Group A: 23.3% and B: 19.5%). Since all essential investigation parameters were available for only Group A, further details of this group is presented. Excluding five cases of subclinical hypothyroidism the prevalence of PCOS among 600 adolescent and young girls (15-24 years) was 22.5% by Rotterdam and 10.7% by the AES criteria [Figure 1]. Among those diagnosed with PCOS, 71.8% were nonobese, 7.5% cases were overweight, and 20.7% were obese. PCOS cases had statistically significant higher mean values with respect to waist circumference, BMI, and serum testosterone and FAI levels compared with the non-PCOS (control) group [Table 2].
Table 2

Difference in endocrine and metabolic profiles between polycystic ovarian synrdome and nonpolycystic ovarian synrdome

Difference in endocrine and metabolic profiles between polycystic ovarian synrdome and nonpolycystic ovarian synrdome All four signs/symptoms of PCOS were present in only 8.1% of the cases, 28.9% had three and majority (63%) had two symptoms/signs. Mild PCOS was the most common variety with predominant J phenotype (52.6%) followed by 27.4% frank PCOS. Presumptive ovulatory (based on regular cycles of 26-35 days) PCOS was found among 13.3% and classic PCOS was present in 6.7% of cases [Table 3]. Polycystic ovarian synrdome phenotypes Using both Rotterdam and AES criteria symptom of oligomenorrhea had good positive predictive value (PPV) (86.7%, 71.9%) and negative predictive value (NPV) (93.3%, 81%), respectively, followed by appearance of PCO on USG to detect PCOS (PPV 93.3%, 85.9% and NPV 77.8% and 67.5%).

Biochemical and hormonal parameters among PCOS

PCOS cases had statistically significant higher mean values of LH, testosterone, and insulin compared with non-PCOS cases Table 2. Overall PCOS cases had higher percentages of girls who had all biochemical and hormonal parameters more than the 80th percentile of normal. The mean plasma glucose levels were normal in all PCOS cases except one, where 2 h post 75 g plasma glucose value was above 140 g/dL. Hyperinsulinemia was present among 19.2% cases and 6.6% had serum triglycerides above normal range. Statistically, significant differences were observed between obese and nonobese PCOS girls with respect to symptoms, clinical features, and biochemical and hormonal parameters [Table 4]. Irregular cycles were reported by 92% of nonobese girls compared to only 47% of obese girls with PCOS. Obese girls were more hirsute and hypertensive and had higher mean values of post 75 g glucose and insulin and lower levels of SHBG compared with nonobese and the differences were statistically significant. No differences were found in the lipid profile of these two groups. Only one PCOS case was diagnosed with metabolic syndrome.
Table 4

Differences in clinical, biochemical, and hormonal features between obese and nonobese polycystic ovarian synrdome (n=135)

Differences in clinical, biochemical, and hormonal features between obese and nonobese polycystic ovarian synrdome (n=135)

DISCUSSION

PCOS among adolescents is an emerging problem that needs careful assessment, timely intervention, and appropriate treatment. To our knowledge, this is the first urban community based study in India, estimating the prevalence of PCOS among relatively younger population with a much lower mean age unlike reported earlier.[25] As Rotterdam criteria is much more broad-based and does not necessarily require evidence of hyperandrogenism, the prevalence by Rotterdam criteria (22.5%) was almost double compared to that using AES criteria (10.7%). If all the enrolled girls would have participated in the study, the prevalence could further reduce as most girls who did not come for further investigations were symptom free. The prevalence figures among the older age groups is slightly high especially considering the AES criteria, probably indicating increase in hyperandrogenism with age and hence diagnosis and timely intervention could possibly reduce the morbidities in older age groups. This prevalence is relatively higher than that reported by most studies, mainly due to use of different diagnostic criteria, study settings, age groups of the sample studied and hence cannot be compared.[4567891011121314] Puberty is a period when there is physiological hyperandrogenism and hyperinsulinemia which mimics some features of PCOS from Tanner stages I to III with return to prepubertal stage by Tanner stage V.[26] Hence, we enrolled girls 2 years postmenarche when H-P-O axis settles down to normal. Due to this transitory appearance of symptoms and signs of PCOS during adolescence, care must be taken to avoid premature labelling of a case as PCOS to avoid over treatment and psychological stress. Presence of oligomenorrhea among adolescent girls, 2 years postmenarche, can be a good screening indicator to diagnose a probable case of PCOS as reported earlier.[2728] A diagnosis is confirmed if all three signs/symptoms of PCOS are present.[29] which was observed in 27.4% of PCOS cases in the study. The diagnosis may be considered but not confirmed among those who have two signs/symptoms.[29] and this phenotype in our study was 63% which is being followed-up for emergence of confirmed PCOS or settling down to normal hypothalamopituitary ovarian axis. Free testosterone assays are not reliable and the accurate ones are complicated, expensive, and labor intensive.[30] Hence, FAI is a better marker of free testosterone.[31], but as observed in our study it is more correlated with the degree of obesity.[32] Adolescent obesity and PCOS individually and together have emerged as important public health issues in India. There is an urgent need to organize preventive strategy to thwart the oncoming epidemics of obesity and obesity associated PCOS in India.[33] Community-based screening among Asian population found prevalence of PCOS among 6.3% of reproductive age women aged 15-45 years in Srilanka[11] and 5.6% in China[10] using Rotterdam criteria unlike the higher prevalence observed in our study among younger population aged 15-24 year olds or probably due to smaller group of girls who got enrolled due to more symptoms. Classic phenotype was commonly observed among 86% of Greek Caucasian women aged 17-45 years[5] and other retrospective and prospective studies in smaller number of patients with varying age profiles.[3435] However in Asian context as that in China, the most common phenotype was ovulatory PCOS unlike the mild phenotype observed in Sri Lanka and our study. Lean PCOS with milder phenotypes as per Rotterdam criteria are known to have less severe hyperinsulinemia and insulin resistance.[27] and long-term health risks in these groups are not well-documented.[36] Hyperinsulinemia in our study group was present among both obese and nonobese PCOS as reported in literature.[3637] However, the prevalence was much less compared with other studies in Indian context.[262728293031323334353637383940] probably due to overall less number of obese cases and younger population from lower socioeconomic strata in the study. Our study demonstrated that PCOS cases were on the higher scale of the normal range for biochemical parameters, especially obese PCOS had higher mean values compared with their lean counterparts suggesting pertinent danger to jump off the thin line and turn into metabolic syndrome with increasing age as is already known.[4142] Hence in overweight/obese cases, lifestyle and dietary changes along with exercises for weight management must be recommended, coupled with medical management to treat clinical symptoms and hyperinsulinemia. All the investigations were carried out by a single laboratory technician in a single laboratory which enhanced accuracy and consistency in the reports. Even the ultrasound examinations were carried out by a single-trained gynaecologist on a single machine. A retention rate of 77.2% in the study highlights the need to create awareness among general population about this disorder and its sequele. One of the limitations of the study was a poor representation of various socioeconomic strata; hence, the findings cannot be extrapolated to higher socioeconomic group with more westernised lifestyle and intake of junk food. The feasibility of conducting such community-based study justifies the need to upscale this effort to get an overall estimate of the disorder in a diverse sociocultural and economic background, providing an opportunity for early detection and prevention of morbidities among adolescents and young women in India.
  35 in total

Review 1.  Clinical practice. Hirsutism.

Authors:  Robert L Rosenfield
Journal:  N Engl J Med       Date:  2005-12-15       Impact factor: 91.245

2.  Body mass index cut-offs for screening for childhood overweight and obesity in Indian children.

Authors:  V V Khadilkar; A V Khadilkar; A B Borade; S A Chiplonkar
Journal:  Indian Pediatr       Date:  2011-05-30       Impact factor: 1.411

3.  A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile.

Authors:  E Diamanti-Kandarakis; C R Kouli; A T Bergiele; F A Filandra; T C Tsianateli; G G Spina; E D Zapanti; M I Bartzis
Journal:  J Clin Endocrinol Metab       Date:  1999-11       Impact factor: 5.958

4.  Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism.

Authors:  E Carmina; F Rosato; A Jannì; M Rizzo; R A Longo
Journal:  J Clin Endocrinol Metab       Date:  2005-11-01       Impact factor: 5.958

Review 5.  Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span.

Authors:  Ricardo Azziz; Catherine Marin; Lalima Hoq; Enkhe Badamgarav; Paul Song
Journal:  J Clin Endocrinol Metab       Date:  2005-06-08       Impact factor: 5.958

6.  Insulin resistance in nonobese patients with polycystic ovarian disease.

Authors:  R J Chang; R M Nakamura; H L Judd; S A Kaplan
Journal:  J Clin Endocrinol Metab       Date:  1983-08       Impact factor: 5.958

7.  Prevalence of polycystic ovary syndrome in women in China: a large community-based study.

Authors:  Rong Li; Qiufang Zhang; Dongzi Yang; Shangwei Li; Shulan Lu; Xiaoke Wu; Zhaolian Wei; Xueru Song; Xiuxia Wang; Shuxin Fu; Jinfang Lin; Yimin Zhu; Yong Jiang; Huai L Feng; Jie Qiao
Journal:  Hum Reprod       Date:  2013-06-27       Impact factor: 6.918

Review 8.  Ultrasound assessment of the polycystic ovary: international consensus definitions.

Authors:  Adam H Balen; Joop S E Laven; Seang-Lin Tan; Didier Dewailly
Journal:  Hum Reprod Update       Date:  2003 Nov-Dec       Impact factor: 15.610

9.  The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria.

Authors:  Wendy A March; Vivienne M Moore; Kristyn J Willson; David I W Phillips; Robert J Norman; Michael J Davies
Journal:  Hum Reprod       Date:  2009-11-12       Impact factor: 6.918

10.  Polycystic ovary syndrome - A metabolic malady, the mother of all lifestyle disorders in women - Can Indian health budget tackle it in future?

Authors:  M Ashraf Ganie; Sanjay Kalra
Journal:  Indian J Endocrinol Metab       Date:  2011-10
View more
  27 in total

1.  ANTI-THYROID ANTIBODIES AND THE GONADOTROPHINS PROFILE (LH/FSH) IN EUTHYROID POLYCYSTIC OVARIAN SYNDROME WOMEN.

Authors:  M Sharma; A Modi; M Goyal; P Sharma; P Purohit
Journal:  Acta Endocrinol (Buchar)       Date:  2022 Jan-Mar       Impact factor: 1.104

2.  Endocrine Abnormalities in Adolescents with Menstrual Disorders.

Authors:  Siddhesh R Rajiwade; Haritha Sagili; R Soundravally; L Subitha
Journal:  J Obstet Gynaecol India       Date:  2017-07-17

3.  Endocrine and Metabolic Profile of Different Phenotypes of Polycystic Ovarian Syndrome.

Authors:  Saxena Pikee; Singh Shivani; Bhattacharjee Jayshree
Journal:  J Obstet Gynaecol India       Date:  2016-05-04

Review 4.  Clinical, Metabolic and Hormonal Profiles of Bangladeshi Adolescents with Polycystic Ovary Syndrome.

Authors:  Abm Kamrul-Hasan; Fatema Tuz Zahura Aalpona; Shahjada Selim
Journal:  touchREV Endocrinol       Date:  2021-04-28

5.  Is MTHFR 677 C>T Polymorphism Clinically Important in Polycystic Ovarian Syndrome (PCOS)? A Case-Control Study, Meta-Analysis and Trial Sequential Analysis.

Authors:  S Justin Carlus; Saumya Sarkar; Sandeep Kumar Bansal; Vertika Singh; Kiran Singh; Rajesh Kumar Jha; Nirmala Sadasivam; Sri Revathy Sadasivam; P S Gireesha; Kumarasamy Thangaraj; Singh Rajender
Journal:  PLoS One       Date:  2016-03-16       Impact factor: 3.240

6.  A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome.

Authors:  Yogesh Kumar; Narendra Kotwal; Yashpal Singh; Vimal Upreti; Shrikant Somani; K V S Hari Kumar
Journal:  J Family Med Prim Care       Date:  2018 May-Jun

7.  Body Composition, Metabolic Characteristics, and Insulin Resistance in Obese and Nonobese Women with Polycystic Ovary Syndrome.

Authors:  Anil Satyaraddi; Kripa Elizabeth Cherian; Nitin Kapoor; Aleyamma Thaiparambil Kunjummen; Mohan S Kamath; Nihal Thomas; Thomas V Paul
Journal:  J Hum Reprod Sci       Date:  2019 Apr-Jun

8.  Risks with Gynaecological problems on the health of University Students.

Authors:  Rukiye Hobek Akarsu; Selda Yuzer Alsac
Journal:  Pak J Med Sci       Date:  2019       Impact factor: 1.088

9.  Genetics of PCOS: A systematic bioinformatics approach to unveil the proteins responsible for PCOS.

Authors:  Pritam Kumar Panda; Riya Rane; Rahul Ravichandran; Shrinkhla Singh; Hetalkumar Panchal
Journal:  Genom Data       Date:  2016-03-31

10.  GnRH dysregulation in polycystic ovarian syndrome (PCOS) is a manifestation of an altered neurotransmitter profile.

Authors:  Nirja Chaudhari; Mitali Dawalbhakta; Laxmipriya Nampoothiri
Journal:  Reprod Biol Endocrinol       Date:  2018-04-11       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.